phase readout
saveNCT07293351: A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
RECRUITINGupdated 2mo ago
community read0 votes
Sponsor: Bristol-Myers Squibb. Phase: PHASE1. Conditions: Advanced Renal Cell Carcinoma (RCC)
view source ↗
comments(0)
5-min edit window · permanent after that